Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2044-5385
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points ; volume:10 ; number:11 ; day:23 ; month:11 ; year:2020 ; pages:1-13 ; date:11.2020
Blood cancer journal ; 10, Heft 11 (23.11.2020), 1-13, 11.2020
- Creator
-
Gangat, Naseema
Tefferi, Ayalew
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41408-020-00388-x
- URN
-
urn:nbn:de:101:1-2021010319262191454053
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gangat, Naseema
- Tefferi, Ayalew
- SpringerLink (Online service)
Other Objects (12)
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
GATA2 deficiency and related myeloid neoplasms
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Progression in Myeloid Neoplasms: Beyond the Myeloblast
Landscape of biallelic DNMT3A mutant myeloid neoplasms
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Current Challenges in the Characterization of Myeloid Neoplasms
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
GATA2 deficiency and related myeloid neoplasms
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Progression in Myeloid Neoplasms: Beyond the Myeloblast
Landscape of biallelic DNMT3A mutant myeloid neoplasms
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Current Challenges in the Characterization of Myeloid Neoplasms
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms
Real-world experience with venetoclax-based therapy for patients with myeloid sarcoma
Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy
Phosphoproteomic Characterization and Kinase Signature Predict Response to Venetoclax Plus 3+7 Chemotherapy in Acute Myeloid Leukemia
International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms
GATA2 deficiency and related myeloid neoplasms
Venetoclax therapy and emerging resistance mechanisms in acute myeloid leukaemia
Progression in Myeloid Neoplasms: Beyond the Myeloblast
Landscape of biallelic DNMT3A mutant myeloid neoplasms
EAHP 2020 workshop proceedings, pediatric myeloid neoplasms
Venetoclax triggers sublethal apoptotic signaling in venetoclax-resistant acute myeloid leukemia cells and induces vulnerability to PARP inhibition and azacitidine
Current Challenges in the Characterization of Myeloid Neoplasms
Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms